Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.
Guggenheim analyst Seamus Fernandez initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Buy rating and announces Price Target of $80.